| Collaborations |
|
Alliance Pharmaceutical Corp.
Oxygent ™ co-development
|
|
Medarex, Inc.
Broad HuMAb-Mouse antibody development agreement.
|
|
Incyte Corporation
|
|
Genetronics, Inc.
On October 6, 1998 Genetronics entered into comprehensive development and license agreements involving its proprietary drug delivery system for Electroporation Therapy treatment of cancer with Ethicon, Inc., a Johnson & Johnson company
|
|
Essential Therapeutics, Inc.
Cephalosporin which is currently in pre-clinical stages - and will target Staphylococcal infections, Enterococcal infections, and Streptococcus pneumoniae infections.
|
|
Pharmagene Laboratories Limited
|
|
Bristol-Myers Squibb Company
|
|
Amersham Biosciences
|
|
PanVera LLC
|
|
Rigel Pharmaceuticals, Inc.
|
|
Massachusetts Life Sciences Center
|